Cereno’s CEO on being granted “Compassionate Use”
Cereno Scientific has been granted Expanded Access, also known as “compassionate use,” by the FDA for drug candidate CS1 in rare disease pulmonary arterial hypertension. This will ensure that patients who have completed the ongoing phase II clinical study in PAH will have continued access to the drug. Cereno’s CEO Sten R. Sörensen dropped by the BioStock Studio to talk about the importance of this decision.
Watch the interview with Cereno‘s CEO Sten R. Sörensen below.
